ANI Pharmaceuticals
ANIP
116 hedge funds and large institutions have $206M invested in ANI Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 45 increasing their positions, 37 reducing their positions, and 29 closing their positions.
151% more call options, than puts
Call options by funds: $2.14M | Put options by funds: $852K
22% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 37
1.19% less ownership
Funds ownership: 60.56% → 59.37% (-1.2%)
13% less funds holding
Funds holding: 134 → 116 (-18)
15% less capital invested
Capital invested by funds: $241M → $206M (-$35.3M)
62% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 29
Top Buyers
Top Sellers
ANIP Hedge Fund Activity: Q3 2020 in Review
116 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q3 2020, worth a combined $206M — down 15% from $241M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of ANIP and 11 opened new positions — a net loss of 18 holders — while 37 trimmed existing stakes and 45 added.
The largest buyer was Ameriprise, adding an estimated $4.62M. The largest seller was Assenagon Asset Management, cutting an estimated $2.22M.
- 116 institutional investors held ANI Pharmaceuticals (ANIP) as of Q3 2020, down from 134 in Q2 2020.
- Funds reported $206M of ANI Pharmaceuticals stock for Q3 2020, down 15% quarter-over-quarter.
- 11 funds opened new ANI Pharmaceuticals positions in Q3 2020 and 29 closed out, a net change of -18 holders.
- The largest ANI Pharmaceuticals buyer in Q3 2020 was Ameriprise, an estimated $4.62M added.
- The largest ANI Pharmaceuticals seller in Q3 2020 was Assenagon Asset Management, an estimated $2.22M sold.
Based on aggregated 13F filings for Q3 2020.